Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trogarzo (TNX-355) in Treatment-Experienced HIV-1 Infection
NCT00089700Phase 2Unknown
- Sponsor
- Tanox, Inc.
- Start
- Mar 2004
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ibalizumab in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Tanox, Inc. Primary endpoint: Change in plasma HIV-1 RNA from baseline at 24 weeks. Status: unknown.
02
Drugs
ibalizumab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00089700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089700.